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1. INTRODUCTION 
Mature cystic teratoma account for 
approximately 20% of all ovarian tumors and 
these tumors contain thyroid tissue in ~15%. 
Struma ovarii is a monodermal variant of ovarian 
teratoma that is composed of more than 50% of 
thyroid tissue and it account for 2.5%- 5% of 
ovarian teratoma [1].  Malignant struma ovarii 
was first described by Wetteland in 1956. [2] and 
since then malignant transformation in struma 
ovarii has caused great interest due to its 
numerous unique features [1,3-5]. In the 
literature, there is no consensus in terminology; 
the term malignant struma has been used in two 
ways: struma ovarii with malignant 
transformation and development of thyroid 
carcinoma within it and struma ovary with 
metastatic tissue [1]. Regarding the occurrence of 
malignancy in struma ovarii, there are few other 
problems like many cases in literature that have 
not been correctly classified and the lack of large 
well documented series [1,5]. In addition, several 
cases reported as malignant struma ovarii in the 
older literature were actually examples of ovarian 
strumal or insular carcinoid [6]. Therefore, it is 
difficult to say the accurate frequency of 
malignant struma. By reviewing the literature, 
papillary carcinoma is the most common thyroid 
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Abstract 
Objectives: To report two patients with papillary thyroid carcinoma arising within mature cystic teratoma with 
long term follow-up.  
Methods: The cases are compared with previous reports of similar entities, with special reference to the 
treatment modalities and management options in follow-up of these patients. 
Results: Final diagnosis of both tumors was established after the initial surgery. Both tumors were 
histologically classified as the malignant transformation of the thyroid tissue within the mature cystic teratoma, 
both were papillary type and confined to one ovary. We presented two similar cases, but our therapeutic 
approach was surgically different. Both patients were treated with surgery alone and are alive with no evidence 
of the disease after 10 and 5 years, respectively.  
Conclusion: Preoperative and intraoperative frozen section diagnosis of malignant transformation within 
teratoma is very difficult, so optimal management of the patients has not yet been established. Treatment of this 
tumor should be individualized, but a contour of treatment modalities and management options are visible and 
our cases may contribute in this achievement.  
Keywords: Malignant transformation, mature cystic teratoma, papillary thyroid carcinoma, ovary, treatment. 
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type carcinoma to occur in struma ovarii, follow 
by follicular carcinoma and recently described 
new entity highly differentiated follicular 
carcinoma of ovarian origin, while other types of 
thyroid carcinoma occurs extremely rare [1, 6-
12]. Patients with papillary carcinoma ranged 
from 21 to 68 years old with common symptoms 
and preoperative findings of pelvic mass and 
abdominal pain in 40%, menstrual irregularities 
in 9%, hyperthyroidism in 5-8% and deep vein 
thrombosis in 4% of patients [10-15]. 
Considering the rarity of the disease there is no 
consensus for optimal management of the 
patients. This report presents two patients with a 
malignant transformation of the thyroid tissue 
within the mature cystic teratoma of the ovary 
with long-term follow up. Both tumors were 
histologically classified as papillary thyroid 
carcinoma arising in mature cystic teratoma. 
These two patients were admitted to our clinic 
within a short period, but regardless to that were 
treated in a different way. Therefore, this was a 
good argument for reviewing the literature 
because there is still no consensus in 
terminology, diagnostic criteria, treatment and 
follow up of these patients.  
2. CASE REPORTS 
2.1. Case 1 
A 57-year old patient, gravida 0, para 0, was 
admitted into the clinic due to an abdominal 
ultrasound examination which revealed a tumor 
of the left ovary. Transvaginal ultrasound 
examination revealed irregular, predominantly 
cystic tumor mass of the left ovary measuring 66 
x 63 mm in diameter with a smaller solid 
hyperehogenic part. The uterus was enlarged due 
to several myomas while the right ovary had a 
normal appearance. No free fluid in the 
peritoneal cavity was found. The patient had been 
previously well, without symptoms and apart 
from receiving treatment for osteoporosis her 
medical history was unremarkable. Laboratory 
findings at the time of admittance were normal. 
A Serum CA-125 level was 52.6 U/l. Cervical 
cytologic Pap smear was normal. After the 
preoperative preparation our patient underwent 
the operative procedure during which an 
explorative laparotomy was done. 
Intraoperatively, uterus was enlarged due to 
several myomas; the right adnexa were 
macroscopically normal appearance, while the 
left ovary was replaced by mobile, predominantly 
cystic tumor tissue measuring 7 cm in greatest 
dimension, without adhesions to the surrounding 
structures. There was no free fluid in the 
peritoneal cavity. The peritoneal washing was 
negative. A left adnexectomy was performed and 
the surgical specimen was sent for an 
intraoperative histopathologic analysis which 
revealed cystic mature teratoma filled with suet, 
hair and a formed tooth. Thereafter, operating 
procedure was continued and hysterectomy and a 
right adnexectomy were done. A final 
histological examination revealed that ovarian 
tumor tissue was a cystic mature teratoma with a 
component of thyroid tissue. Within thyroid 
tissue a partly incapsulated nodule measuring 1.3 
cm in greatest dimension was found. 
Microscopically, the nodule was consisted of 
solid areas and small thyroid follicles with rare 
papillary formations lined by one or several 
layers of neoplastic cells with nuclear features 
characteristic of papillary thyroid carcinoma 
(Figure1). 
 
Figure1. Microscopic features of the resected tumor 
of the first case. The tumor was partly incapsulated 
with focal infiltration of the capsule, HE, 20x (A). 
Strumal thyroid component of the ovarian mature 
teratoma is shown on the right and incapsulated 
papillary thyroid carcinoma on the left lower part of 
the image, HE, 20x (B). Characteristic features of the 
papillary thyroid carcinoma on higher magnification: 
papillary formations lined by one layer of neoplastic 
cells with optically clear nuclei, HE, 20x (C). 
Characteristic nuclear features crowded, enlarged, 
round or oval nuclei, overlapping with ground glass 
appearance and nuclear grooves, HE, 40x (C).  
Capsular invasion was present, but there was no 
lymphovascular invasion and no necrosis in 
tumor tissue. Definitive diagnosis was papillary 
thyroid carcinoma arising in mature cystic 
teratoma. The postoperative course was 
uneventful. A month after the operation the 
patient underwent ultrasonographic analysis of 
the thyroid gland, the analysis of the hormones of 
the thyroid gland and a whole-body 
scintiscanning. The reports of the above 
mentioned tests were all normal and the patient 
showed no clinical signs of hyperthyroidism. She 
was further advised to have regular follow-up 
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examinations every 3 months during the first year 
after surgery, and then every 6 months at the 
Gynecologic Oncology Outpatient Department 
(OPD]. Ten years after the surgery, the patient is 
alive with no evidence of the disease.  
2.2. Case 2 
A 35-year old asymptomatic patient, gravida 4, 
para 1, with a cystic tumor of the left ovary was 
admitted into the clinic. Her medical history 
included a partial resection of the right ovary due 
to a mature teratoma 6 years before hospital 
admission, and laparoscopic bilateral cystectomy 
due to follicular cysts of both ovaries, one year 
after that. Transvaginal ultrasound examination 
revealed cystic tumor mass of the left ovary 
measuring 78 x 36 mm, fulfilled with 
hipoehogenic content, while uterus and the right 
adnexa had a normal appearance. No free fluid in 
the peritoneal cavity was found. All laboratory 
findings, including CA 125, of the patient were 
normal. Cervical cytologic Pap smear was 
normal. After the preoperative preparation the 
patient underwent the operative laparoscopic 
procedure. Intraoperatively, left ovary was 
replaced by cystic tumor tissue measuring 8 cm 
in greatest dimension, with a smooth surface and 
without adhesions to the surrounding structures. 
There was no free fluid in the peritoneal cavity 
and peritoneal washing was negative. The uterus, 
right ovary, organs and peritoneal surfaces of the 
abdominal cavity were all macroscopically 
unremarkable. Since there were no preoperative 
or intraoperative signs of malignancy, only a left 
adnexectomy was done and the specimen was not 
sent for a frozen section analysis. The first 
postoperative day the patient was discharged 
from hospital. Pathological gross examination 
revealed that the left ovary was replaced by 
predominantly cystic tumor tissue, measuring 8 
cm in greatest dimension, with smooth inner 
walls and filled with suet and hair. A histological 
examination revealed that ovarian tumor tissue 
was a cystic mature teratoma with a component 
of thyroid tissue. Within thyroid tissue, a 
microscopic focus of papillary thyroid carcinoma 
measuring 2 mm in greatest dimension was also 
found (Figure2).  
Once again, the definitive diagnosis was 
papillary thyroid carcinoma arising in mature 
cystic teratoma. The patient had no complications 
during the postoperative course, but due to 
malignant diagnosis she was admitted into our 
clinic and complete staging was performed one 
month after the initial operation. The staging 
procedure included total abdominal 
hysterectomy with right adnexectomy, infracolic 
omentectomy with multiple peritoneal biopsies, 
pelvic and paraaortic lymphadenectomy. All 
specimens including the peritoneal washing were 
negative and the disease was staged as FIGO IA, 
T1aN0M0. The postoperative course was 
uneventful. The ultrasonographic analyses of the 
thyroid gland along with thyroid hormones 
analysis were all normal. Moreover, our patient 
showed no clinical signs of hyperthyroidism. She 
was further advised to have regular follow-up 
examinations every 3 months during the first year 
after surgery, and then every 6 months at the 
Gynecologic OPD. Five years after the surgery, 
the patient is alive with no evidence of the 
disease.  
 
Figure2. Microscopic features of the resected tumor 
of the second case. Microscopic focus of the papillary 
thyroid carcinoma whitin thyroid tissue of the mature 
cystic teratoma, HE, 20x (A). Characteristic features 
of the papillary thyroid carcinoma on higher 
magnification: papillary formations lined by 
neoplastic cells with overlapping, enlarged, round or 
oval nuclei, with ground glass appearance, HE, 40x 
(B). 
3. DISCUSSION  
Thyroid carcinoma arising within an ovarian 
mature teratoma is a rare tumor and there are no 
standard criteria for diagnosis and treatment of 
such tumor. Most of these tumors are diagnosed 
postoperatively, after final histopathologic 
analysis. The histopathologic criteria for 
diagnosis of malignant transformation in struma 
ovarii have varied over time, and uniformly 
accepted criteria for diagnosis of a thyroid-type 
carcinoma arising in ovarian teratoma have yet to 
be established. However, criteria for papillary 
type carcinoma are made on the basis of the same 
criteria as for the cervical thyroid carcinoma. 
Criteria for the conventional papillary carcinoma 
includes true papillary architecture, lined by one 
or several layers of neoplastic cells with 
crowded, enlarged, round or oval nuclei, 
overlapping with ground glass appearance and 
nuclear grooves [12]. However, it should be 
stressed that some authors have described 
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ovarian thyroid tumors with subtle atypical 
nuclear features that are not entirely diagnostic 
for the follicular variant of papillary thyroid 
carcinoma, but still have the ability to 
metastasize [17]. 
In order to eliminate metastasis from the thyroid 
gland with secondary involvement of the ovary it 
is necessary to do further clinical evaluation and 
an ultrasonographic exam of the thyroid gland  
[1,3,12].  
Serum CA 125 is not a specific marker for 
diagnosis and observation of the thyroid 
carcinoma, although it can be elevated in germ 
cell tumors (teratomas). Nevertheless, there are 
proofs that tireoglobulin is a good indicator in 
such tumors. There is a case in which the authors 
have proved elevated values of tireoglobulin in 
the blood of the ovarian vein of the ovary affected 
with the tumor, compared to the blood from 
another peripheral vein [13]. It can therefore be 
concluded that tireoglobulin is certainly a good 
marker for diagnosis and especially for discovery 
of the recurrence of the disease. So this marker 
can be very useful in management and follow-up 
of these patients. The treatment of thyroid 
carcinoma arising in mature cystic teratoma is 
still controversial. The surgical treatment ranges 
from a total abdominal hysterectomy with 
bilateral salpingoophorectomy, pelvic and 
paraaortic lymphadenectomy and omentectomy 
to a conservative surgical procedure that includes 
unilateral adnexectomy and the preservation of 
fertility. Adjuvant therapy includes radiotherapy, 
chemotherapy and the suppression of the thyroid 
gland. We found different approaches in the 
literature. Postmenopausal and premenopausal 
patients that do not want to have children any 
more should undergo a hysterectomy, bilateral 
salpingoophorectomy and omentectomy with 
peritoneal washing as well as pelvic and 
paraaortic lymphadenectomy, that is, a complete 
staging [15]. In the case of patients who wish to 
preserve fertility surgical therapy can include 
unilateral adnexectomy, but only in those cases 
where tumor is confined to ovary, has not 
infiltrated ovarian capsule and there are no proofs 
of metastasis [18-20].  
In case of residual tumor mass after surgical 
treatment some authors advise a total 
thyreodectomy  and radioablation with I131 as 
well as in cases with gross extra-ovarian 
extension of the disease [3,16,21,22] A recent 
study that examined 57 cases of malignant struma 
ovarii proved that there was no recurrences in 
cases treated with adnexectomy, thyroidectomy 
and I131radioablation and therefore they suggest a 
multimodal approach to the treatment of this 
tumors [20].  In cases of recurrence and 
metastatic disease a chosen therapy would be 
chemotherapy and radiotherapy combined with 
the suppression of the thyroid gland [12,15]. The 
therapy may include  a recombinant human TSH 
in order to achieve higher concentrations of I131 
in the tumor [23].  
However, the problem lies in the fact that in the 
majority of cases these tumors are diagnosed 
postoperatively when the surgery of mature 
teratoma had already been performed. In such a 
case, it is impossible to perform a complete 
staging without the patient undergoing new 
surgery. Laparoscopic lymphadenectomy can be 
of use in these cases because of staging [24]. 
The follow up of patients includes the regular 
control of the tireoglobulin in the serum, and in 
the case of elevated values, a scintiscanning with 
131I or a PET/CT [25] should be done. A 
recommended follow-up is a period of at least 10 
years. The average time of recurrence is 4 years 
and there is evidence in literature that some 
recurrences occurred even 16 years after 
treatment [26].  
Our cases were also diagnosed after surgery 
when a complete histopathologic diagnosis 
arrived. In our first case the result of the frozen 
section, analysis did not reveal the malignancy 
within the teratoma. During surgery, the first 
patient underwent a total abdominal 
hysterectomy with bilateral 
salpingoophorectomy. The carcinoma was partly 
incapsulated, confined to one ovary, and the 
scintiscanning after surgery showed no residual 
tumor mass or metastasis. The ultrasonographic 
examination excluded primary thyroid gland 
carcinoma, and the findings of the hormone of the 
thyroid gland were normal. Taking all that into 
account we decided not to perform any radical 
surgical procedure or adjuvant therapy. The 
patient was advised to have her tireoglobulin and 
hormones of the thyroid gland regularly checked. 
In contrast, the second patient during the first 
surgical procedure underwent only adnexectomy 
and although the carcinoma was microscopic in 
size, a complete staging was indicated. After the 
complete staging, it was confirmed that the 
disease is restricted to one ovary and no adjuvant 
therapy was recommended. The patient was 
advised to have regular checkups.  
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4. CONCLUSION 
The above presented cases showed that 
diagnostic criteria, as well as treatment of the 
thyroid carcinoma arising within ovarian 
teratoma are still not defined. Probably due to the 
rarity of the disease, there is still no accepted 
procedure for optimal management of the 
patients. An additional problem is that in most 
cases the final diagnosis is established after 
surgery because diagnosis on frozen sections is 
often not possible, and these tumors do not have 
a typical symptomatology or reliable diagnostic 
biomarker. In cases where a metastatic disease in 
the peritoneal cavity is established, a total staging 
as well as adjuvant therapy are mandatory. In 
cases where the tumor is restricted to one ovary, 
incapsulated and without clear evidence of 
metastasis in the peritoneal cavity or distant sites, 
conservative surgical procedure and regular 
postoperative follow-up are possible. However, 
in most of these cases it remains unclear whether 
to repeat the surgical procedure for complete 
staging of the disease or not.  This is the main 
surgical dilemma. We presented two similar 
cases that were surgically treated different, but 
both with good outcome after 10 and 5 years of 
follow-up, respectively. Treatment of this tumor 
should be individualized, but a contour of 
treatment modalities and management options 
are visible and our cases may contribute in this 
achievement.  
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